XBIT Investors Have Opportunity to Join XBiotech Inc. Fraud Investigation with the Schall Law Firm

Core Viewpoint - The Schall Law Firm is investigating XBiotech Inc. for potential violations of securities laws related to misleading statements and undisclosed information affecting investors [1][2]. Group 1: Investigation Details - The investigation centers on whether XBiotech issued false or misleading statements and failed to disclose critical information to investors [2]. - XBiotech announced a pause in its phase 2 rheumatoid arthritis program for its drug candidate, Natrunix, due to not meeting the primary endpoint and experiencing "substantial irregularities" that complicate the interpretation of findings [2]. Group 2: Investor Rights - Shareholders who have suffered losses are encouraged to participate in the investigation and can contact the Schall Law Firm for a free discussion of their rights [3].